Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA
2024-512731-74-00Phase 2Authorised
- Sponsor
- Sygehus Lillebælt
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and dexamethasone in multiple myeloma (MM), sponsored by Sygehus Lillebælt. Primary endpoint: Overall response rate. Planned start Apr 2024; status: authorised.
02
Drugs
venetoclaxdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512731-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512731-74-00.